Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Day One Biopharmaceuticals, Inc. - Common Stock (NQ:DAWN)

8.740 -0.100 (-1.13%)
Streaming Delayed Price Updated: 11:50 AM EST, Nov 18, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 459,942
Open 8.840
Bid (Size) 8.730 (500)
Ask (Size) 8.740 (200)
Prev. Close 8.840
Today's Range 8.655 - 9.080
52wk Range 5.635 - 14.46
Shares Outstanding 73,572,633
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Day One to Participate in the Piper Sandler 37th Annual Healthcare Conference
From Day One Biopharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Mersana Therapeutics Stock Explodes Over 200% To Notch Best Day Ever As $285M Buyout Trumps Analyst Downgrades: Retail Cheers ‘Very Good Bargain’ ↗
Mersana surged even as multiple firms downgraded the stock following Day One’s acquisition agreement. 
Via Stocktwits

Performance

YTD
-31.2%
-31.2%
1 Month
+17.9%
+17.9%
3 Month
+28.3%
+28.3%
6 Month
+34.9%
+34.9%
1 Year
-32.8%
-32.8%

More News

Read More
News headline image
Day One Biopharma Expands Oncology Pipeline With $285 Million Mersana Buyout ↗
Via Benzinga
News headline image
Mersana Catapults 200% On Day One Bio's Surprise Buyout ↗
Via Investor's Business Daily
News headline image
Earnings Scheduled For November 4, 2025 ↗
Via Benzinga
News headline image
Earnings Scheduled For August 5, 2025 ↗
Via Benzinga
News headline image
Earnings Scheduled For May 6, 2025 ↗
Via Benzinga
News headline image
MRSN Stock Soars Over 200% Pre-Market After Day One Acquisition Deal ↗
Via Stocktwits
News headline image
Day One to Acquire Mersana Therapeutics to Advance Mission to Bring New Medicines to People of All Ages with Life-Threatening Diseases
From Day One Biopharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Day One Announces New OJEMDA™ (tovorafenib) Data to be Presented in Oral Session at the 2025 Society for Neuro-Oncology (SNO) Annual Meeting
From Day One Biopharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Keep an eye on the top gainers and losers in Wednesday's session. ↗
Via Chartmill
News headline image
12 Health Care Stocks Moving In Wednesday's Intraday Session ↗
Via Benzinga
News headline image
Day One Reports Third Quarter 2025 Financial Results and Corporate Progress
From Day One Biopharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Day One to Report Third Quarter 2025 Financial Results Tuesday, November 4, 2025
From Day One Biopharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Super Micro Computer Posts Downbeat Q4 Results, Joins Personalis, Snap And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session ↗
Via Benzinga
News headline image
Why Astera Labs Shares Are Trading Higher By Over 17%; Here Are 20 Stocks Moving Premarket ↗
Via Benzinga
News headline image
Day One (DAWN) Q2 Revenue Jumps 313% ↗
Via The Motley Fool
News headline image
12 Health Care Stocks Moving In Tuesday's After-Market Session ↗
Via Benzinga
News headline image
Day One Biopharmaceuticals Inc (NASDAQ:DAWN) Reports Q2 2025 Earnings: Revenue Growth but Wider-Than-Expected Loss ↗
Via Chartmill
News headline image
Day One Reports Second Quarter 2025 Financial Results and Corporate Progress
From Day One Biopharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Day One to Report Second Quarter 2025 Financial Results Tuesday, August 5, 2025
From Day One Biopharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Day One Appoints Michael Vasconcelles, M.D., as Head of Research and Development
From Day One Biopharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Day One Reports First Quarter 2025 Financial Results and Corporate Progress
From Day One Biopharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Day One to Report First Quarter 2025 Financial Results Tuesday, May 6, 2025
From Day One Biopharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Day One Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Progress
From Day One Biopharmaceuticals, Inc.
Via GlobeNewswire

Frequently Asked Questions

Is Day One Biopharmaceuticals, Inc. - Common Stock publicly traded?
Yes, Day One Biopharmaceuticals, Inc. - Common Stock is publicly traded.
What exchange does Day One Biopharmaceuticals, Inc. - Common Stock trade on?
Day One Biopharmaceuticals, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Day One Biopharmaceuticals, Inc. - Common Stock?
The ticker symbol for Day One Biopharmaceuticals, Inc. - Common Stock is DAWN on the Nasdaq Stock Market
What is the current price of Day One Biopharmaceuticals, Inc. - Common Stock?
The current price of Day One Biopharmaceuticals, Inc. - Common Stock is 8.740
When was Day One Biopharmaceuticals, Inc. - Common Stock last traded?
The last trade of Day One Biopharmaceuticals, Inc. - Common Stock was at 11/18/25 11:50 AM ET
What is the market capitalization of Day One Biopharmaceuticals, Inc. - Common Stock?
The market capitalization of Day One Biopharmaceuticals, Inc. - Common Stock is 643.02M
How many shares of Day One Biopharmaceuticals, Inc. - Common Stock are outstanding?
Day One Biopharmaceuticals, Inc. - Common Stock has 643M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.